Main Profile

(Open for CMO services)

Description in a few words:

Centurion is a research based, biological focused company with an impressive track record in the development, manufacture, import and supply of biological products, orphan drugs, vaccines and niche hospital generics commercially available for the Turkish, Middle East, Africa, Asia, CIS and Balkan markets.

Current Leadership:

Ersin Erfa, CEO

Founding Year:


Centurion facility focuses on the manufacture of biological, biosimilar, orphan drugs and sterile generic injectables. The site of the new facility is located in Ankara, the capital city of Turkey.

Centurion plans to develop its site in a phased manner. The later phases will expand the facility, depending upon the demand for the manufactured products and newcomers like vaccine and other biologicals. Therefore, the facility was designed with flexibility to expand in accordance to global market demand.

Number of machinery in Production and capacities:

Solution Preparation & Filtration:

- From 10 Lt to 2000 Lt

- Filling & Closing

- Bosch Filling & Closing machine + Freeze Dryer

- Groninger Combi Filling & Closing machine filling from 0.1 ml pfs to 200 ml cartridges-vials + Freeze Dryer

- Packaging

- Automatic particule/visual inspection + labelling + cartoning + sterilization line

Main product categories or therapies of focus

Our diverse portfolio of therapeutic areas includes Allergy, Immunology, Oncology, Hematology, Neuromuscular diseases, Immuno-dermatology, Pediatric Metabolism and Emergency Service.

Centurion’s portfolio contains plasma products, biosimilars, orphan drugs, vaccines and niche generics.

Serialization Service

Serialization and aggregation equipment with a serialization infrastructure that is compatible with the regulations of all countries that have implemented the serialization application is currently being used.

Total number of delivered boxes/year

- Vials 15.000.000 units/year

- Cartridges 5.000.000 units/year

- PFS 5.000.000 units/year


R&D focus

Centurion R&D aspire to be a dynamic and flexible organization by focusing on the discovery and development for those therapies that can deliver high quality of life and better health for patients. Our R&D program identifies and evaluates molecules that show potential to advance the treatment of life-threating diseases in areas of huge unmet medical need like chronical and orphan diseases.

Our specialty R&D work ranges from the discovery and validation of new therapeutic targets and compounds, preclinical studies (including toxicology, pharmacokinetics, pharmacodynamics and pharmacology studies) to clinical pharmacology and the design, execution and analysis of clinical trials. We conduct these activities for both small molecules and biologics.


Export % in revenues:

Expected to be 8% in 2020 and 25% in 2021

List of export countries:

Centurion has successfully entered into international markets. Starting with several semi-regulated markets in the Middle East, Africa and CIS and Asian countries, the aspiration is to enter into markets like Europe, South Africa, Russia, GCC, the US and Canada in the next 2-3 years. In doing so, Centurion aims to have business from international markets as a key contributor to the company’s turnover in the coming years.

In More Depth

Number of employees

Centurion has grown to employ 155 people in the last three years.

GMP certificates

GMP and manufacturing license granted by Turkish Drug and Medical Device Agency

Revenue or Growth Rate in past financial year

Revenue growth rate for 2018 was 164%, with a 5-year CAGR of 24.6%

USP/ or a differentiating fact:

Centurion is the first pharmaceutical company started to supply a portfolio of biological products including plasma products, vaccines, serums, orphan drugs and niche hospital generics to the country of Turkey since late 1980s.

Existing manufacturing facility and R&D has been designed in line with global standards and quality requirements to fulfill the need of biological fill &finish process and quality control systems.

The main strategy has been based on specialty therapeutic areas with high value therapies, smaller markets and unmet needs of patients.

Prominent partnerships / clients

Centurion has several common projects with:

- Start-up companies from Europe and US for innovative medicines

- Turkish Science and Technology Institution for local R&D

- Existing partners for new products and technology transfer

- Partners from Europe, Balkan countries, Middle East, CIS, Africa and Asian countries for export